SG Cowen Lifts Merck Rating to Strong Buy

Analyst Stephen Scala sees continuing strength in the drug giant's products

SG Cowen upgraded Merck & Co. (MRK ) to strong buy. After the close of trading Jan. 23, the drug maker posted $0.75 vs. $0.66 4Q EPS.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.